�@

•\3.�@HMG-CoAŠÒŒ³�y‘f‘jŠQ–ò‰î“üŽŽŒ±‚Ì�¬�Ñ

‰î“üŽŽŒ±–¼ HMG CoAŠÒŒ³�y‘f‘jŠQ–ò“Š—^ ‘Î�Æ ”]�[�ÇŒ¸�­—¦ 95%�M—Š‹æŠÔ

n= �@”]�[�Ç�@�i�“�j�@ n= ”]�[�Ç�@ �i�“�j

ˆêŽŸ—\–h�‡Œv 3908 48—á (2.7%) 3900 56—á�@ (3.1%) �@�|‚P‚T�“ �@�@�i�|‚S‚Q�`‚Q‚V�“�j

�@‚v‚n‚r‚b‚n‚o 3302 46—á (2.8%) 3293 51—á (3.2%) �@�|‚P‚O�“ �@�@�i�|‚S‚O�`‚R‚S�“�j

“ñŽŸ—\–h�‡Œv 5862 134—á (5.1%) 5848 192—á (7.3%) �@�|‚R‚P�“ �@�@�i�|‚S‚T�`�|‚P‚R�“�j

CARE 2081 54—á (5.2%) 2078 78—á (7.5%) �@�|‚R‚P�“ �@�@�i�|‚T‚Q�`�|‚R�“�j

�@‚S‚r 2221 75—á (5.6%) 2223 102—á (7.6%) �@�|‚Q‚V�“ �@�@�i�|‚S‚U�`�|‚Q�“�j

ˆêŽŸ“ñŽŸ�‡Œv 9770 182—á (4.1%) �@�@�@�@�@9748 248—á (5.6%) �@�|‚Q‚V�“ �@�@�i�|‚S‚O�`�|‚P‚P�“�j

Crouse et al.Arch Intern Med '97;157(12):p1305-1310.